-
Media Release
Novartis issues voluntary nationwide recall of Promacta® 12.5 mg for oral suspension due to potential peanut contamination
-
Media Release
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
-
Media Release
AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
-
Media Release
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
-
Media Release
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
-
Media Release
Novartis Offers Free Genetic Mutation Testing Program for Advanced Melanoma Patients; Results Can Help Doctors and Patients Making Cancer Treatment Decisions
-
Media Release
Long-term Survival Benefit Shown for Metastatic Melanoma Patients Treated with Novartis Tafinlar® + Mekinist®
-
Media Release
AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
-
Media Release
Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings
-
Media Release
Novartis Teams Up With Celebrity Interior Designer Nate Berkus To Launch My Home In Sight, A Program Empowering People With Wet AMD To Live More Independently At Home
-
Media Release
Novartis STEP Program™ now accepting submissions for proposals that address unmet patient needs in cancer biomarker testing
-
Media Release
Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept